Shokrgozar Negin, Tamaddon Gholamhossein
School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Int J Hematol Oncol Stem Cell Res. 2018 Oct 1;12(4):322-328.
Hematopoietic stem cell transplantation (HSCT) is a useful treatment. In contrast to solid organ transplantations, the use of ABO blood group mismatch is acceptable in HSCT. Immediate or late hemolytic reactions, pure red cell aplasia, delayed red blood cell recovery, and graft-versus -host disease are the results of this situation. This review shows the consequences of ABO-mismatched HSCT and its impacts on HSCT parameters, as well as providing clinical guides in this situation.
造血干细胞移植(HSCT)是一种有效的治疗方法。与实体器官移植不同,在造血干细胞移植中使用ABO血型不匹配是可以接受的。立即或迟发性溶血反应、纯红细胞再生障碍、红细胞恢复延迟以及移植物抗宿主病都是这种情况的结果。本综述展示了ABO血型不匹配的造血干细胞移植的后果及其对造血干细胞移植参数的影响,并在这种情况下提供临床指导。